Veterans and PTSD and psychedelic therapy - what studies show
Weterani i PTSD a terapia psychodelikami — co to, co mowia badania i jak stosowac. u Bucha.
Among all patient groups that have caught the attention of psychedelic researchers, military veterans hold a special place. PTSD after combat service is difficult to treat, recurrent, and is associated with alarmingly high suicide risk - 22 veterans a day in the United States (VA National Suicide Prevention Report, 2023). Standard medications and psychotherapy help half of them. The others are looking for something different. This article discusses what research shows about MDMA and psilocybin therapy for veterans with PTSD - reliably, without hype.
KEY INFORMATION
• Phase 3 MAPS studies showed PTSD remission in 67% of participants after MDMA-assisted therapy vs 32% in placebo (Mitchell et al., Nature Medicine, 2023).
• The FDA refused to register this therapy in August 2024, requesting additional study - the decision does not invalidate the study results.
• PTSD affects 11-20% of veterans from Iraq and Afghanistan, and standard treatment helps only 40-60% (VA, 2023).
• This article is purely educational - it discusses published scientific research and does not recommend the use of controlled substances.
Why is treating veterans' PTSD so challenging?
Standard treatment for PTSD includes psychotherapy (primarily prolonged exposure - PE, and EMDR) and pharmacotherapy with sertraline or paroxetine - the only medications approved by the FDA for treating PTSD. Meta-analyses indicate that about 40-60% of patients achieve significant improvement with these methods (Watts et al., Journal of Clinical Psychiatry, 2013). This means that 40 to 60% do not respond adequately.
For combat veterans, the situation is particularly challenging for several reasons. Firstly, combat injuries are often multiple and complex - not just one traumatic episode, but months or years of chronic threat. Secondly, veterans statistically engage less in psychotherapy, viewing it as a sign of weakness. Thirdly, PE and EMDR require direct exposure to traumatic content - some veterans discontinue treatment because they cannot endure this process.
MDMA changes this picture. Therapists working with patients in MAPS protocols describe that MDMA reduces anxiety and defensiveness enough for patients to approach trauma without overwhelming amygdala activation. This is not chemical therapy - it is a means to enable more effective psychotherapy.
What did the Phase 3 MAPS studies show about PTSD?
The most important published data comes from the phase 3 MAPS study (MAPP1), published in Nature Medicine. Mitchell et al. studied 90 participants with severe PTSD - among them military veterans, paramedics, and victims of sexual assault. Participants were randomly assigned to the MDMA group (3 sessions of 80-120 mg MDMA in the context of psychotherapy) or placebo (3 sessions of therapy without active substance) (Mitchell et al., Nature Medicine, 2021).
The results were clear. After therapy, 67% of participants in the MDMA group no longer met the diagnostic criteria for PTSD according to CAPS-5 (Clinician-Administered PTSD Scale), compared to 32% in the placebo group. In the category of 'functional remission,' the difference was even greater. A second phase 3 study (MAPP2, published in 2023) confirmed similar results in an independent cohort of participants.
It is worth noting that the MAPS protocol does not rely solely on administering MDMA. Each session with the substance (lasting 8 hours) is preceded by several hours of preparatory therapy and followed by intensive integration. The substance is a tool, not a remedy in itself - without specialized, multi-hour therapeutic support, the effects can be entirely different.
Pilot Studies of Psilocybin in Veterans
Psilocybin is less studied than MDMA in the context of veterans' PTSD, but pilot results are intriguing. An observational study from 2025 included 58 veterans participating in legal retreats with psilocybin or ayahuasca outside the U.S. The results showed significant improvement in PTSD symptoms among participants - with the caveat that the study had no control group (Prisinzano et al., Brain and Behavior, 2025).
A randomized controlled study from the University of California, San Diego (UCSD) is currently evaluating psilocybin in combat veterans with PTSD and SUD (substance use disorders). The study is ongoing - phase 2 results are expected in 2025. MAPS is concurrently funding psilocybin research following the failure of MDMA registration in 2024, expanding its clinical research portfolio.
Citation capsule - MDMA-PTSD: The Phase 3 MAPS study (Mitchell et al., Nature Medicine, 2021) showed PTSD remission in 67% of participants after MDMA-assisted therapy, compared to 32% in the placebo group. It was the largest controlled study of MDMA in the context of PTSD and included military veterans, paramedics, and victims of assault.
Table: PTSD Treatment Methods and Effectiveness - What the Research Says
The following summary compares documented therapeutic approaches, their evidence base, and estimated response rates. The data pertain to various populations (not just veterans), so the values are approximate.
| Method | Evidence Base | Remission / Improvement | Regulatory Status |
|---|---|---|---|
| Prolonged Exposure (PE) | Multiple RCTs, meta-analyses | ~50-60% remisja | Recommended by VA/APA |
| EMDR | RCTs, WHO meta-analyses | ~50-60% remisja | Recommended by WHO |
| Sertraline / Paroxetine | Multiple RCTs | ~40-50% poprawa | Approved by FDA |
| MDMA-assisted therapy | 2 × Phase 3 (MAPS) | ~67% remission (Phase 3 studies) | FDA denial 2024; studies ongoing |
| Psilocybin-assisted therapy | Pilot studies, Phase 2 | Promising preliminary data | Badania kliniczne fazy 2-3 |
Heroic Hearts and wellness programs outside clinical protocols
Beyond controlled clinical trials, there is a growing movement of non-profit organizations organizing psilocybin experiences for veterans in countries where it is legal (Jamaica, Mexico, Netherlands). The Heroic Hearts Project - founded by veteran Jesse Gould in 2017 - is one of the largest such organizations and has helped over 300 veterans participate in organized therapeutic retreats by 2024.
Data collected by the Heroic Hearts Project in its own observational study (Johnson et al., 2023, unpublished) indicate a reduction in PTSD symptoms in 73% of participants after 6 months, measured by PCL-5 (PTSD Checklist). This is not a randomized controlled study - but the scale of the project and the consistency of the results make the data valuable as evidence of 'real-world effectiveness' outside the laboratory.
An important dimension of these programs is the group structure and peer support. Veterans participate in retreats together with other veterans, which - as organizers emphasize - eliminates some of the stigma associated with seeking psychological help. The environment of 'their people' who understand the specifics of military service can be a therapeutic factor in itself, regardless of the substance's action. Research on the social factors of the therapeutic effect of psychedelics is one of the active areas of research in MAPS phase 4 protocols.
Ryzyko i ograniczenia - czego nie wiemy
A reliable analysis must consider what we still do not know. Firstly: most clinical studies excluded individuals with active bipolar affective disorder, a history of psychosis, or active substance addiction - groups in which PTSD often co-occurs. The safety of psychedelic therapy in these populations is poorly documented.
Secondly: long-term data (beyond 12 months) are still scarce. MAPS studies included follow-ups of up to 18 months, but the population was relatively small. We do not know if the improvement lasts for 5 or 10 years, nor if 'booster sessions' are required. Thirdly: costs. Even if therapy were to gain registration, the full protocol (2-3 sessions with the substance, several sessions of accompanying therapy) will be expensive - raising questions about accessibility for veterans without extensive health insurance.
We noted in the review of accounts from veterans participating in psilocybin programs that many describe the change not as 'healing' from trauma, but as a change in their relationship to trauma. Traumatic memories do not disappear, but lose their 'emotional charge' and obsessive nature. This is a semantic, yet clinically significant difference.
What stands in the way of broader access?
The FDA's decision in August 2024 to deny approval for MDMA-assisted therapy was disappointing for the community of researchers and veterans awaiting access. The FDA pointed out several issues with the MAPS studies: the difficulty of maintaining a blind trial (participants know whether they received MDMA), potential reporting errors by therapists heavily involved in the psychedelic movement, and concerns about risky behaviors of therapists towards vulnerable participants (Yazar-Klosinski et al., J Psychopharmacol, 2025).
This does not mean that the data is false. It means that the FDA requires a higher methodological standard before allowing this therapy for widespread use. For veterans waiting for help, this is frustrating bureaucracy; from a public safety perspective, it is understandable caution regarding a new therapeutic model.
Frequently Asked Questions
Does MDMA-assisted therapy work for PTSD in veterans?
Phase 3 MAPS studies showed that 67% of participants with PTSD after MDMA therapy no longer met the diagnostic criteria for PTSD, compared to 32% in the placebo group (Mitchell et al., Nature Medicine, 2021). Among the participants were many military veterans. However, the FDA denied approval in August 2024, demanding further study.
Does psilocybin help veterans with PTSD?
Pilot studies are promising, but there is a lack of phase 3 studies specifically for veterans with PTSD. An observational study (Prisinzano et al., Brain and Behavior, 2025) included 58 veterans participating in legal retreats with psilocybin or ayahuasca and showed significant reduction in PTSD symptoms after 3 months. Phase 2 RCT studies are underway.
How many people with PTSD are military veterans?
According to VA, PTSD affects about 11-20% of veterans who served in Iraq and Afghanistan and about 30% of Vietnam veterans. It is estimated that around 500,000 American veterans struggle with active PTSD each year, and standard pharmacological treatment helps only about 40-60% of them (VA, 2023).
Why did the FDA reject MDMA-assisted therapy in 2024?
The FDA denied approval for Lykos Therapeutics therapy in August 2024, citing methodological flaws (the inability to maintain a blind trial), potential data misuse, and safety concerns regarding therapist behaviors. The FDA requested an additional, independently conducted clinical trial. Detailed justification is discussed in the scientific literature (Yazar-Klosinski et al., J Psychopharmacol, 2025).
Which organizations conduct psychedelic therapy research for veterans?
The main organizations are MAPS, Heroic Hearts Project, VETS Foundation, and Imperial College London. The Heroic Hearts Project has been organizing psilocybin retreats for veterans in Jamaica and Mexico since 2019 as wellness programs. More about the neurological mechanisms of these therapies can be found in the article on DMN and afterglow.
Is psychedelic therapy available for veterans in Poland?
In Poland, psychedelics (psilocybin, MDMA) remain controlled substances of group I and are not available outside clinical trials. Veterans interested in participating in clinical trials can check active recruitments on the ClinicalTrials.gov platform. Several academic centers in Poland are conducting preliminary discussions on ketamine research in PTSD - as a legal alternative.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
